← Leaderboards
Athan Kuliopulos
Oasis Pharmaceuticals
$11,829,387
Attributed
$11,829,387
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,829,387 · 8
By mechanism
R42$7,543,296 · 4
R44$3,165,348 · 1
R41$1,120,743 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseMouse ModelMedical CenterPharmacologic SubstanceSafetyToxicologyPharmaceutical PreparationsSignal TransductionSmall Business Technology Transfer ResearchTechnologyCellsToxic EffectInflammatoryInflammationG-Protein-Coupled ReceptorsTissuesDrug DevelopmentCommercializationBostonDesignPharmacologyCanis FamiliarisRattusSpecificity
Grant awards (19)
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy$50,000
R42 · FY2025 · HL · contact PI
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy$999,799
R42 · FY2024 · HL · contact PI
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy$999,799
R42 · FY2023 · HL · contact PI
Development of liver homing PAR2 pepducins for the treatment of Hepatocellular Carcinoma$392,485
R41 · FY2022 · CA · contact PI
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy$361,774
R41 · FY2021 · HL · contact PI
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis$740,572
R42 · FY2020 · HL · contact PI
Development of PAR2 Pepducins as a Novel NASH Treatment$1,056,106
R44 · FY2019 · DK · contact PI
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis$750,502
R42 · FY2019 · HL · contact PI
Development of PAR2 Pepducins as a Novel NASH Treatment$1,060,598
R44 · FY2018 · DK · contact PI
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis$225,769
R42 · FY2018 · HL · contact PI
Development of PAR2 Pepducins as a Novel NASH Treatment$1,048,644
R44 · FY2017 · DK · contact PI
Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis$750,000
R42 · FY2017 · AR · contact PI
Development of PAR4 Pepducins as a Novel Antithrombotic Treatment$366,484
R41 · FY2017 · HL · contact PI
Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis$750,000
R42 · FY2016 · AR · contact PI
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis$871,014
R42 · FY2015 · DK · contact PI
Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis$225,000
R42 · FY2015 · AR · contact PI
Supplement to grant 5R42DK101240 Oasis Pharmaceuticals to attend BIO conference$5,000
R42 · FY2015 · DK · contact PI
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis$871,604
R42 · FY2014 · DK · contact PI
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis$304,237
R42 · FY2013 · DK · contact PI